Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial

BACKGROUND: Current hyponatraemia guidelines are divided on the use of tolvaptan in hospitalised patients with moderate to severe hyponatraemia, due to an uncertain risk-benefit ratio. We will conduct a randomised trial to test the hypothesis that early use of tolvaptan improves the rate of serum so...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, Annabelle M., Grossmann, Mathis, Hoermann, Rudolf, Zajac, Jeffrey D., Russell, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028077/
https://www.ncbi.nlm.nih.gov/pubmed/35449020
http://dx.doi.org/10.1186/s13063-022-06237-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028077/
https://www.ncbi.nlm.nih.gov/pubmed/35449020
http://dx.doi.org/10.1186/s13063-022-06237-5

Ejemplares similares